---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-24-000015"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:23:06.296588+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth

## Summary
- Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).
- Q4 gross margin 63% vs 76% YoY due to higher mix of Spatial instruments.
- Q4 operating loss $55.2M (vs $23.1M), including $38.9M stock-based comp and $19.6M in-process R&D expense.
- Full year 2023 net loss $255.1M, widened from $166.0M in 2022.
- FY2024 revenue guidance $670M-$690M (8-12% growth); cumulative instruments sold reached 5,966.

## SEC filing metadata
- accession: 0001770787-24-000015
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/0001770787-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/txg-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-24-000015
- JSON: https://secwatch.observer/filing/0001770787-24-000015.json
- Plain text: https://secwatch.observer/filing/0001770787-24-000015.txt

## Key facts
- Earnings Releases
  10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, net income Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond. Guidance initiated.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: $184.0 million for the fourth quarter and $618.7 million for the full year of 2023
  - Net income: Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond
  - Guidance: initiated
  - Result: reported results
  source text: 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000015/0001770787-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.